BioXcel Therapeutics (BTAI) Other Accumulated Expenses (2018 - 2026)

BioXcel Therapeutics' Other Accumulated Expenses history runs 9 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 454.85% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $2.3 million (up 454.85% YoY), while the FY2025 annual figure was $622000.0, up 93.17% from the prior year.
• Other Accumulated Expenses was $2.3 million for Q1 2026 at BioXcel Therapeutics, up from $622000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $2.3 million in Q1 2026 to a low of $177000.0 in Q4 2023.
• Historically, Other Accumulated Expenses has averaged $537647.1 across 5 years, with a median of $392000.0 in 2022.
• The sharpest annual moves came in 2023 and 2026: Other Accumulated Expenses slumped 78.41% in 2023, then soared 454.85% in 2026.
• A 5-year view of Other Accumulated Expenses shows it stood at $820000.0 in 2022, then plunged by 78.41% to $177000.0 in 2023, then jumped by 81.92% to $322000.0 in 2024, then jumped by 93.17% to $622000.0 in 2025, then surged by 277.33% to $2.3 million in 2026.
• The last three Other Accumulated Expenses figures came in at $2.3 million (Q1 2026), $622000.0 (Q4 2025), and $450000.0 (Q3 2025), per Business Quant data.